Trial NCT04322682
Publication Tardif JC, Lancet Respir Med, 2021 (published paper)
Dates: 2020-03-23 to 2020-12-22
Funding: Mixed (Government of Quebec; the Bill & Melinda Gates Foundation; the National Heart, Lung, and BloodInstitute of the US National Institutes of Health; Montreal Heart Institute Foundation; NYU Grossman Schoolof Medicine; Rudin Family Foundation; philanthropist Sophie Desmarais.)
Conflict of interest: Yes
| Methods | |
| RCT Blinding: double blinding | |
| Location :
Multicenter / Brazil, Canada, Greece, South Africa, Spain, USA Follow-up duration (days): 30 | |
| Inclusion criteria | 1. Patients ≥ 40 years of age
2. received a diagnosis of COVID-19 within 24 hours of enrollment 3. not currently hospitalized and not under immediate consideration for hospitalization 4. presented at least one of the following high-risk criteria: - age of 70 years or older, - obesity (body-mass index of 30 kg/m2 or more), - diabetes, - uncontrolled hypertension (systolic blood pressure ≥150 mm Hg), - known respiratory disease, - known heart failure, - known coronary disease, - fever of at least 38.4°C within the last 48 hours, - dyspnea at the time of presentation, - bicytopenia, - pancytopenia, - or the combination of high neutrophil and low lymphocyte counts 5. women not of childbearing potential or practicing adequate contraception. |
| Exclusion criteria | 1. Inflammatory bowel disease, chronic diarrhea or malabsorption
2. pre-existent progressive neuromuscular disease 3. estimated glomerular filtration rate less than 30 ml/minute/1.73 m2 4. severe liver disease 5. current treatment with colchicine 6. current chemotherapy for cancer 7. history of significant sensitivity to colchicine. |
| Interventions | |
| Treatment
Colchicine 0.5 mg twice daily days 1-3, then once daily the following 27 days. |
|
| Control
Placebo | |
| Participants | |
| Randomized * participants (n1=2235 / n2= 2253) | |
| Characteristics of participants N=* Mean age : NR 2067 males Severity : Mild: n=0 / Moderate: n=0/ Severe: n=0 Critical: n=0 | |
| Primary outcome | |
| In the register Number of participants who die or require hospitalization due to COVID-19 infection [ Time Frame: 30 days post randomization ] | |
| In the report Composite of death or hospitalization due to COVID-19 infection in the 30 days following randomization | |
| Documents avalaible |
Protocol NR Statistical plan NR Data-sharing stated Yes |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
|
| General comment |